While initial efforts to target DLL3 with an ADC failed, more recent efforts targeting DLL3 via T-cell engager strategies in SCLC have demonstrated remarkable success5,6 with recent approval by the FDA for treatment of relapsed SCLC. This evidence concerns the gene DLL3 and small cell lung carcinoma.